Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (6744)	2/12/2001 10:05:11 AM
From: Cal Gary	Respond to of 14101

Somewhat related Pharmacia Q4 profits rise 32 percent (Adds analyst quotes, paragraphs 9-10, 18; First Call outlook, paragraph 14) By Ransdell Pierson "NEW YORK, Feb 12 (Reuters) - Drug maker Pharmacia Corp. (NYSE:PHA) said on Monday its adjusted fourth-quarter profits rose 32 percent, matching Wall Street estimates, on strong sales of its arthritis, cancer and glaucoma medicines." ... "Celebrex, launched in January 2000 for treating osteoarthritis and rheumatoid arthritis, raked in revenues of $772 million for the quarter and $2.6 billion for the full year." Their reported 3Q Celebrex sales were $687mm USD. Added another $85mm!! quarter over quarter. About 12% Q to Q growth.

To: Montana Wildhack who wrote (6744)	2/12/2001 10:14:37 AM
From: bdalarge	Read Replies (1) \| Respond to of 14101

Hi Wolf, I hate to ask this but why am I showing only 400 shares traded to this point. Cab someone please provide a RTQ and confirm that we are trading. Thanks BDA

To: Montana Wildhack who wrote (6744)	2/12/2001 10:21:46 AM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

HI Wolf, I hear your. Great answer. These projections were based around 5% as a means of measuring how little it would take to make Dimethaid viable. The sales of Celebrex and Vioxx plus other NSAIDs do give accurate market size numbers. What Celebrex and Vioxx tells me is doctors will Quickly switch to safer and effective treatments, especially in the case of OA suffers. To temper this, the majority of their sales is in North America, so far. Therefore I should reword. NA doctors tend to quickly switch to safer and effective treatments, especially in the case of OA suffers. I hope this holds true with European doctors. Remember, Celebrex has recently begun ramp up in Europe, so DMX will soon meet head to head for the attention/decision of EU physicians. The positive thing is Pennsaid is not competing for use with established Celebrex clients. I know one Celebrex user who will stick with his doctors recommendation / plan until it was completed before switching or trying anything else.